Indeed, Ibañez-Costa et al. demonstrated decreased in vitro GH expression in somatotropinomas treated with first generation analogues of somatostatin or pasireotide[23]. This evidence concerns the gene GH1 and growth hormone-producing pituitary gland neoplasm.